Al-Sawaf O - Search Results

1

Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.

Al-Sawaf O, Jen MH, Hess LM, Zhang J, Goebel B, Pagel JM, Abhyankar S, Davids MS, Eyre TA. Al-Sawaf O, et al. Haematologica. 2024 Jun 1;109(6):1866-1873. doi: 10.3324/haematol.2023.284150. Haematologica. 2024. PMID: 38031799 Free PMC article. Clinical Trial.

2

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Al-Sawaf O, Herling CD, Holtick U, Scheid C, Cramer P, Sasse S, von Tresckow B, Tuchscherer A, Fischer K, Eichhorst B, Hallek M, Frenzel LP. Al-Sawaf O, et al. Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21. Haematologica. 2019. PMID: 30792201 Free PMC article. No abstract available.

3

Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?

Al-Sawaf O, Davids MS. Al-Sawaf O, et al. Clin Cancer Res. 2024 Feb 1;30(3):471-473. doi: 10.1158/1078-0432.CCR-23-2872. Clin Cancer Res. 2024. PMID: 38055246

4

High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies.

Al-Sawaf O. Al-Sawaf O. Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2024.285029. Online ahead of print. Haematologica. 2024. PMID: 38450529 Free article.

5

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.

Cramer P, Tresckow JV, Robrecht S, Bahlo J, Fürstenau M, Langerbeins P, Pflug N, Al-Sawaf O, Heinz WJ, Vehling-Kaiser U, Dürig J, Tausch E, Hensel M, Sasse S, Fink AM, Fischer K, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M. Cramer P, et al. Haematologica. 2021 Feb 1;106(2):543-554. doi: 10.3324/haematol.2019.223693. Haematologica. 2021. PMID: 32107341 Free PMC article. Clinical Trial.

6

Current Perspectives on Therapy for Chronic Lymphocytic Leukemia.

Awan FT, Al-Sawaf O, Fischer K, Woyach JA. Awan FT, et al. Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-10. doi: 10.1200/EDBK_279099. Am Soc Clin Oncol Educ Book. 2020. PMID: 32239979 Free article. Review.

7

Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.

Fischer K, Al-Sawaf O, Hallek M. Fischer K, et al. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):357-362. doi: 10.1182/hematology.2020000120. Hematology Am Soc Hematol Educ Program. 2020. PMID: 33275717 Free PMC article.

8

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.

Hallek M, Al-Sawaf O. Hallek M, et al. Am J Hematol. 2021 Dec 1;96(12):1679-1705. doi: 10.1002/ajh.26367. Am J Hematol. 2021. PMID: 34625994 Free article. Review.

9

The role of minimal residual disease in chronic lymphocytic leukemia.

Al-Sawaf O, Hallek M, Fischer K. Al-Sawaf O, et al. Clin Adv Hematol Oncol. 2022 Feb;20(2):97-103. Clin Adv Hematol Oncol. 2022. PMID: 35120090 Review.

10

Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older.

Simon F, Giza A, Robrecht S, Fink AM, Cramer P, von Tresckow J, Fürstenau M, Goede V, Tausch E, Schneider C, Stilgenbauer S, Wendtner CM, Eichhorst B, Fischer K, Hallek M, Al-Sawaf O. Simon F, et al. Leuk Lymphoma. 2022 Dec;63(14):3299-3306. doi: 10.1080/10428194.2022.2123223. Epub 2022 Sep 18. Leuk Lymphoma. 2022. PMID: 36120898

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page